Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism

Surgery. 2003 Oct;134(4):713-7; discussion 717-9. doi: 10.1016/s0039-6060(03)00335-0.

Abstract

Background: To date there have been no reports on the feasibility of radioguided parathyroidectomy (RGP) in patients with secondary and tertiary hyperparathyroidism.

Methods: Twenty-three consecutive patients with secondary (n=5) or tertiary hyperparathyroidism (n=18) underwent RGP. Patients were injected with 10 mCi of technetium 99-sestamibi before surgery. All parathyroid glands were localized during operation with a neoprobe.

Results: The mean patient age was 50+/-3 years. The mean preoperative calcium and intact parathyroid hormone levels were 11.0+/-0.3 mg/dL and 400+/-107 pg/mL, respectively. Eighteen patients had 3- or 4-gland hyperplasia, 2 had double adenomas, 2 had forearm graft hyperplasia, 1 had 6-gland disease, and 3 had ectopic glands. All hyperplastic glands had ex vivo counts >20% of background (mean, 63%+/-6%), making frozen section unnecessary. When compared with 66 historical control subjects who underwent surgery without radioguidance for tertiary hyperparathyroidism, patients undergoing RGP had decreased operative times (96+/-8 minutes vs 151+/-15 minutes; P<.001) and lengths of stay (1.3+/-0.1 days vs 3.7+/-0.3 days; P<.001).

Conclusions: RGP in patients with secondary and tertiary hyperparathyroidism is feasible, may reduce operative time, and permits omission of frozen section. Thus RGP appears to be a useful adjunct in the treatment of secondary and tertiary hyperparathyroidism.

MeSH terms

  • Case-Control Studies
  • Feasibility Studies
  • Female
  • Humans
  • Hyperparathyroidism / diagnostic imaging*
  • Hyperparathyroidism / surgery*
  • Hyperparathyroidism, Secondary / diagnostic imaging*
  • Hyperparathyroidism, Secondary / surgery*
  • Male
  • Middle Aged
  • Radionuclide Imaging
  • Radiopharmaceuticals*
  • Surgery, Computer-Assisted*
  • Technetium Tc 99m Sestamibi*
  • Time Factors
  • Treatment Outcome

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Sestamibi